{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:51:45Z","timestamp":1785577905580,"version":"3.56.0"},"reference-count":109,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01918","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T15:46:27Z","timestamp":1565279187000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Learning From Success and Failure: Biologics for Non-approved Skin Diseases"],"prefix":"10.3389","volume":"10","author":[{"given":"Reinhart","family":"Speeckaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanja","family":"van Geel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/120347541201600407","article-title":"Safety and efficacy of adalimumab for the treatment of severe alopecia areata: case series of three patients","volume":"16","author":"Bolduc","year":"2012","journal-title":"J Cutan Med Surg."},{"key":"B2","first-page":"23","article-title":"Adalimumab-related alopecia in a patient affected by psoriasis","author":"Mel\u00e9-Ninot","year":"2017","journal-title":"Dermatol Online J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00393-018-0464-z","article-title":"Alopecia universalis in a patient with rheumatoid arthritis developed during treatment with adalimumab","volume":"77","author":"Ostojic","year":"2018","journal-title":"Z Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1001\/jamadermatol.2014.1544","article-title":"Alopecia universalis successfully treated with adalimumab","volume":"150","author":"Gorcey","year":"2014","journal-title":"JAMA Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jid.2017.11.012","article-title":"Increased risk of vitiligo following anti-tumor necrosis factor therapy: a 10-year population-based cohort study","volume":"138","author":"Bae","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B6","first-page":"534","article-title":"Treatment of generalized vitiligo with anti-TNF-\u03b1 Agents","volume":"11","author":"Alghamdi","year":"2012","journal-title":"J Drugs Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/bjd.14016","article-title":"Tumour necrosis factor-\u03b1 inhibition can stabilize disease in progressive vitiligo","volume":"173","author":"Webb","year":"2015","journal-title":"Br J Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1365-2230.2010.03972.x","article-title":"Role of interleukin-17 in the pathogenesis of vitiligo","volume":"36","author":"Bassiouny","year":"2011","journal-title":"Clin Exp Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/ijd.12808","article-title":"T-helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor-\u03b1) in patients with alopecia areata: association with clinical type and severity","volume":"55","author":"Atwa","year":"2016","journal-title":"Int J Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00403-018-1853-5","article-title":"Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata","volume":"310","author":"Guttman-Yassky","year":"2018","journal-title":"Arch Dermatol Res."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12789","article-title":"IL-17A is not a treatment target in progressive vitiligo","author":"Speeckaert","year":"2019","journal-title":"Pigm Cell Mel Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jdcr.2017.07.009","article-title":"Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata","volume":"3","author":"Elkady","year":"2017","journal-title":"JAAD Case Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jaci.2015.11.001","article-title":"Extensive alopecia areata is reversed by IL-12\/IL-23p40 cytokine antagonism","volume":"137","author":"Guttman-Yassky","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1111\/pde.13699","article-title":"Response to ustekinumab in three pediatric patients with alopecia areata","volume":"36","author":"Aleisa","year":"2018","journal-title":"Pediatr Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/ijd.12392","article-title":"Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo","volume":"54","author":"Vaccaro","year":"2015","journal-title":"Int J Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7859","DOI":"10.4081\/dr.2018.7859","article-title":"Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: real life data","volume":"10","author":"Kyriakou","year":"2018","journal-title":"Dermatol Rep."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17822","article-title":"Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa","author":"Prussick","year":"2019","journal-title":"Br J Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2340\/00015555-2794","article-title":"Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17A antibody secukinumab","volume":"98","author":"Schuch","year":"2018","journal-title":"Acta Derm Venereol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17641","article-title":"The anti-inflammatory potency of biologics targeting TNF-\u03b1, IL-17A, IL-12\/23 and CD20 in hidradenitis suppurativa: an ex vivo study","volume":"181","author":"Vossen","year":"2019","journal-title":"Br J Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaad.2018.12.017","article-title":"Guselkumab in the treatment of hidradenitis suppurativa: a retrospective chart review","volume":"81","author":"Casseres","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1111\/jdv.15368","article-title":"Guselkumab in the treatment of severe Hidradenitis suppurativa","volume":"33","author":"Kovacs","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol."},{"key":"B24","first-page":"772","article-title":"Failure of anakinra in a case of severe hidradenitis suppurativa","volume":"15","author":"Russo","year":"2016","journal-title":"J Drugs Dermatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.4103\/ijdvl.IJDVL_147_16","article-title":"Hidradenitis suppurativa unresponsive to canakinumab treatment: a case report","volume":"83","author":"Tekin","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/dth.12222","article-title":"Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients","volume":"28","author":"Sand","year":"2015","journal-title":"Dermatol Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/ced.12540","article-title":"Acne conglobata and adalimumab: use of tumour necrosis factor-\u03b1 antagonists in treatment-resistant acne conglobata, and review of the literature","volume":"40","author":"Yiu","year":"2015","journal-title":"Clin Exp Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/jid.2014.290","article-title":"Propionibacterium acnes promotes Th17 and Th17\/Th1 responses in acne patients","volume":"135","author":"Kistowska","year":"2015","journal-title":"J Invest Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1177\/0961203312441982","article-title":"Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus","volume":"21","author":"Winchester","year":"2012","journal-title":"Lupus."},{"key":"B31","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1001\/archdermatol.2011.185","article-title":"Successful treatment of subacute lupus erythematosus with ustekinumab","volume":"147","author":"De Souza","year":"2011","journal-title":"Arch Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2340\/00015555-1467","article-title":"Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report","volume":"93","author":"Dahl","year":"2013","journal-title":"Acta Derm Venereol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10067-017-3884-2","article-title":"Diverse patterns of anti-TNF-\u03b1-induced lupus: case series and review of the literature","volume":"37","author":"Shovman","year":"2018","journal-title":"Clin Rheumatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/annrheumdis-2018-214833","article-title":"Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study","volume":"78","author":"Scherlinger","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1001\/jamadermatol.2018.3793","article-title":"Assessment of response to B-cell depletion using rituximab in cutaneous lupus erythematosus","volume":"154","author":"Quelhas da Costa","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/art.40828","article-title":"Safety and tolerability of omalizumab, a randomized clinical trial of humanized anti-IgE monoclonal antibody in systemic lupus erythematosus?","volume":"71","author":"Hasni","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.semarthrit.2017.10.010","article-title":"A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis","volume":"47","author":"Schiffenbauer","year":"2018","journal-title":"Semin Arthritis Rheum."},{"key":"B39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s42358-018-0030-z","article-title":"Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies","volume":"58","author":"de Souza","year":"2018","journal-title":"Adv Rheumatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1136\/annrheumdis-2014-eular.4966","article-title":"FRI0197 use of BIOLOGICS in PM and DM in Sweden - a national register study","volume":"73","author":"Svensson","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"ZE08","DOI":"10.7860\/JCDR\/2016\/19519.8643","article-title":"Is optimal management of recurrent aphthous stomatitis possible? A reality check","volume":"10","author":"Ranganath","year":"2016","journal-title":"J Clin Diagn Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1002\/art.40531","article-title":"Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Beh\u00e7et's syndrome: a retrospective study of seventy patients with vascular involvement","volume":"70","author":"Emmi","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jaut.2018.09.002","article-title":"Efficacy of the anti-IL 17 secukinumab in refractory Beh\u00e7et's syndrome: a preliminary study","volume":"97","author":"Di Scala","year":"2019","journal-title":"J Autoimmun."},{"key":"B44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jaut.2017.05.002","article-title":"Ustekinumab for Beh\u00e7et's disease","volume":"82","author":"Mirouse","year":"2017","journal-title":"J Autoimmun."},{"key":"B45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13075-017-1222-3","article-title":"Treatment of mucocutaneous manifestations in Beh\u00e7et's disease with anakinra: a pilot open-label study","volume":"19","author":"Grayson","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut."},{"key":"B47","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jaad.2018.06.065","article-title":"Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: a multicenter retrospective study","volume":"80","author":"de","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/1744666X.2018.1438269","article-title":"Pyoderma gangrenosum: a review of pathogenesis and treatment","volume":"14","author":"Ahn","year":"2018","journal-title":"Expert Rev Clin Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/ddg.13741","article-title":"Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients","volume":"17","author":"Herberger","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"B50","first-page":"36","article-title":"Non-response to Interleukin-1 Antagonist canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis suppurativa","volume":"10","author":"Sun","year":"2017","journal-title":"J Clin Aesthet Dermatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/RHU.0000000000000511","article-title":"Successful treatment of autoimmune disease-associated pyoderma gangrenosum with the IL-1 receptor antagonist anakinra: a case series of 3 patients","volume":"23","author":"Beynon","year":"2017","journal-title":"J Clin Rheumatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s10067-015-3054-3","article-title":"Occurrence of sweet syndrome under anti-TNF","volume":"34","author":"Banse","year":"2015","journal-title":"Clin Rheumatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1001\/jamadermatol.2016.0503","article-title":"Refractory subcutaneous sweet syndrome treated with adalimumab","volume":"152","author":"Agarwal","year":"2016","journal-title":"JAMA Dermatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000326112","article-title":"Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret\u00ae) in a case of refractory Sweet's syndrome","volume":"222","author":"Kluger","year":"2011","journal-title":"Dermatology (Basel)."},{"key":"B55","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/ard.2006.068254","article-title":"Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome","volume":"67","author":"Delluc","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.annder.2012.03.012","article-title":"Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases","volume":"139","author":"Lipsker","year":"2012","journal-title":"Ann Dermatol Venereol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity","volume":"153","author":"van Beek","year":"2017","journal-title":"JAMA Dermatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/bjd.15114","article-title":"Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid","volume":"177","author":"Hashimoto","year":"2017","journal-title":"Br J Dermatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clim.2018.12.015","article-title":"IgE blockade in autoimmunity: omalizumab induced remission of bullous pemphigoid","volume":"198","author":"James","year":"2018","journal-title":"Clin Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature","volume":"20","author":"Kremer","year":"2018","journal-title":"Am J Clin Dermatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000452828","article-title":"Successful treatment of a bullous pemphigoid patient with rituximab who was refractory to corticosteroid and omalizumab treatments","volume":"9","author":"Bilgi\u00e7 Temel","year":"2017","journal-title":"Case Rep Dermatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1111\/jdv.14002","article-title":"A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis","volume":"31","author":"Loget","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jdcr.2015.07.014","article-title":"Bullous pemphigoid during ustekinumab therapy","volume":"1","author":"Le Guern","year":"2015","journal-title":"JAAD Case Rep."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1111\/1346-8138.14760","article-title":"Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid","volume":"46","author":"Kamata","year":"2019","journal-title":"J Dermatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e2201","DOI":"10.1111\/1346-8138.13909","article-title":"Development of bullous pemphigoid during secukinumab treatment for psoriasis","volume":"44","author":"Ho","year":"2017","journal-title":"J Dermatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid","volume":"134","author":"Le Jan","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00417-017-3603-3","article-title":"Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study","volume":"255","author":"You","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-018-0896-1","article-title":"Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients","volume":"13","author":"Iwata","year":"2018","journal-title":"Orphanet J Rare Dis."},{"key":"B70","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaad.2018.03.036","article-title":"Biologics for pityriasis rubra pilaris treatment: a review of the literature","volume":"79","author":"Napolitano","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B71","first-page":"367","article-title":"Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris","volume":"101","author":"Bonomo","year":"2018","journal-title":"Cutis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jdcr.2018.05.006","article-title":"Successful treatment of type I pityriasis rubra pilaris with ixekizumab","volume":"4","author":"Heibel","year":"2018","journal-title":"JAAD Case Rep."},{"key":"B73","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jdcr.2018.02.007","article-title":"Secukinumab in pityriasis rubra pilaris: a case series demonstrating variable response and the need for minimal clinical datasets","volume":"4","author":"Wain","year":"2018","journal-title":"JAAD Case Rep."},{"key":"B74","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/1346-8138.14709","article-title":"Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12\/23 p40","volume":"46","author":"Matsuda","year":"2019","journal-title":"J Dermatol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/ijd.14350","article-title":"The role of biologics in the treatment of chronic granuloma annulare","volume":"58","author":"Chen","year":"2019","journal-title":"Int J Dermatol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"752","DOI":"10.4103\/0019-5154.91847","article-title":"Disseminated granuloma annulare: a cutaneous adverse effect of anti-tnf agents","volume":"56","author":"Ratnarathorn","year":"2011","journal-title":"Indian J Dermatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/ard.2007.075663","article-title":"Granuloma annulare induced by anti-tumour necrosis factor therapy","volume":"67","author":"Voulgari","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"5918708","DOI":"10.1155\/2017\/5918708","article-title":"A case of granuloma annulare associated with secukinumab use","volume":"2017","author":"Bonomo","year":"2017","journal-title":"Case Rep Dermatol Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"903541","DOI":"10.1155\/2015\/903541","article-title":"Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab","volume":"2015","author":"Lieberoth","year":"2015","journal-title":"Case Rep Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e12848","DOI":"10.1111\/dth.12848","article-title":"The efficacy of omalizumab in cutaneous mastocytosis: a case series","volume":"32","author":"Hinojosa","year":"2019","journal-title":"Dermatol Ther."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.12.407","article-title":"The effect of omalizumab in mastocytosis patients. Prospective double-blind, placebo-controlled multicentre study","volume":"143","author":"Distler","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13601-018-0199-6","article-title":"Diverse expression of TNF-\u03b1 and CCL27 in serum and blister of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"8","author":"Wang","year":"2018","journal-title":"Clin Transl Allergy."},{"key":"B83","first-page":"E15","article-title":"Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis","volume":"101","author":"Woolridge","year":"2018","journal-title":"Cutis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest."},{"key":"B86","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fphar.2019.00282","article-title":"Paradoxical skin reactions to biologics in patients with rheumatologic disorders","volume":"10","author":"Garcovich","year":"2019","journal-title":"Front Pharmacol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2340\/00015555-1249","article-title":"Successful treatment of lichen planus with adalimumab","volume":"92","author":"Holl\u00f3","year":"2012","journal-title":"Acta Derm Venereol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/00128071-200708020-00010","article-title":"Etanercept for the management of oral lichen planus","volume":"8","author":"Yarom","year":"2007","journal-title":"Am J Clin Dermatol."},{"key":"B89","first-page":"325","article-title":"Adalimumab in the management of cutaneous and oral lichen planus","volume":"84","author":"Chao","year":"2009","journal-title":"Cutis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/bjd.16704","article-title":"Failure of rituximab in refractory erosive lichen planus","volume":"179","author":"T\u00e9tu","year":"2018","journal-title":"Br J Dermatol."},{"key":"B91","first-page":"E15","article-title":"Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis","volume":"101","author":"Woolridge","year":"2018","journal-title":"Cutis."},{"key":"B92","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/bjd.15769","article-title":"Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/jdv.13758","article-title":"Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature","volume":"30","author":"Balakirski","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"284","DOI":"10.2340\/00015555-2845","article-title":"Biological and clinical response to omalizumab in a patient with bullous pemphigoid","volume":"98","author":"Menzinger","year":"2018","journal-title":"Acta Derm Venereol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1038\/sj.jid.5700958","article-title":"A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu\/nu mice","volume":"127","author":"Fairley","year":"2007","journal-title":"J Invest Dermatol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jdcr.2019.03.016","article-title":"Recalcitrant prurigo nodularis treated successfully with dupilumab","volume":"5","author":"Rambhia","year":"2019","journal-title":"JAAD Case Rep."},{"key":"B97","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jdcr.2019.01.024","article-title":"A successful case of dupilumab treatment for severe uremic pruritus","volume":"5","author":"Silverberg","year":"2019","journal-title":"JAAD Case Rep."},{"key":"B98","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ijwd.2018.08.010","article-title":"Recalcitrant anal and genital pruritus treated with dupilumab","volume":"4","author":"Yang","year":"2018","journal-title":"Int J Womens Dermatol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamadermatol.2018.3906","article-title":"Reduced itch associated with dupilumab treatment in 4 patients with prurigo nodularis","volume":"155","author":"Mollanazar","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14880","article-title":"Case of alopecia areata during dupilumab treatment for atopic dermatitis","author":"Kanda","year":"2019","journal-title":"J Dermatol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"e12869","DOI":"10.1111\/dth.12869","article-title":"Development of alopecia in patients treated with dupilumab","volume":"32","author":"Maloney","year":"2019","journal-title":"Dermatol Ther."},{"key":"B102","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/DER.0000000000000458","article-title":"Alopecia areata after treatment with dupilumab","volume":"30","author":"Yazdanyar","year":"2019","journal-title":"Dermatitis."},{"key":"B103","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjd.16711","article-title":"Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata","volume":"179","author":"Darrigade","year":"2018","journal-title":"Br J Dermatol."},{"key":"B104","first-page":"139","article-title":"Alopecia universalis and atopic dermatitis improvement with dupilumab: demonstration of a shared pathophysiology and clinical efficacy","volume":"17","author":"Dobkin","year":"2019","journal-title":"Skinmed."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ddg.13778","article-title":"Zwei patienten mit abheilung einer alopecia areata unter dupilumab","volume":"17","author":"Ludriksone","year":"2019","journal-title":"J Dtsch Dermatol Ges."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1111\/pde.13533","article-title":"Eosinophilic annular erythema treated with dupilumab","volume":"35","author":"Gordon","year":"2018","journal-title":"Pediatr Dermatol."},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0946","article-title":"Use of dupilumab in the treatment of papuloerythroderma of ofuji","author":"Teraki","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"6746","DOI":"10.2174\/1381612824666171129193258","article-title":"Biosimilars: from extrapolation into off label use","volume":"23","author":"Zhao","year":"2017","journal-title":"Curr Pharm Des."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01918\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T15:46:32Z","timestamp":1565279192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01918\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,8]]},"references-count":109,"alternative-id":["10.3389\/fimmu.2019.01918"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01918","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,8]]},"article-number":"1918"}}